Sigma Planning Corp boosted its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,090 shares of the pharmaceutical company’s stock after purchasing an additional 250 shares during the period. Sigma Planning Corp’s holdings in GlaxoSmithKline were worth $1,284,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of GSK. D Orazio & Associates Inc. grew its stake in GlaxoSmithKline by 200.0% in the 1st quarter. D Orazio & Associates Inc. now owns 600 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 400 shares in the last quarter. Berman Capital Advisors LLC grew its stake in GlaxoSmithKline by 58.1% in the 2nd quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares in the last quarter. Financial Gravity Wealth Inc. grew its stake in GlaxoSmithKline by 62.7% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 308 shares in the last quarter. Princeton Global Asset Management LLC bought a new position in GlaxoSmithKline in the 1st quarter worth about $37,000. Finally, Reilly Financial Advisors LLC grew its stake in GlaxoSmithKline by 36.7% in the 1st quarter. Reilly Financial Advisors LLC now owns 950 shares of the pharmaceutical company’s stock worth $36,000 after acquiring an additional 255 shares in the last quarter. Institutional investors own 11.26% of the company’s stock.
In other GlaxoSmithKline news, Director Plc Glaxosmithkline purchased 333,333 shares of the stock in a transaction dated Monday, July 1st. The stock was purchased at an average price of $15.00 per share, with a total value of $4,999,995.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.00% of the stock is currently owned by corporate insiders.
Shares of GSK traded up $0.23 during mid-day trading on Friday, hitting $40.19. The company’s stock had a trading volume of 1,366,700 shares, compared to its average volume of 2,486,569. The company’s 50-day moving average is $40.88 and its 200-day moving average is $40.47. GlaxoSmithKline plc has a 52-week low of $36.41 and a 52-week high of $42.47. The firm has a market capitalization of $99.12 billion, a price-to-earnings ratio of 12.72, a PEG ratio of 1.93 and a beta of 0.71. The company has a current ratio of 0.71, a quick ratio of 0.48 and a debt-to-equity ratio of 7.86.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. The firm had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $9.55 billion. As a group, sell-side analysts predict that GlaxoSmithKline plc will post 2.94 earnings per share for the current fiscal year.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: Trade War
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.